For 20 years, we tried to sell plants through ETHICS. In 2 years, GLP-1 drugs like Ozempic sold them through BIOLOGY.
The result? The most aggressive shift in consumer behaviour in 50 years.
GLP-1 users aren’t just eating less; they are eating differently. They are hunting for:
✅ High-quality protein (to prevent muscle wastage)
✅ Extreme fiber (to manage GI side effects)
✅ Nutrient density (making every calorie count)
Guess what ticks all the above boxes? Plant-based foods!
Plant-based brands spent decades:
- Shouting about health benefits (ignored)
- Backing claims with peer-reviewed research (still ignored)
- Fighting meat lobby misinformation (while consumers chose taste over truth)
Meanwhile, GLP-1 drugs simply combined our obsession with how we look (vanity > health) with our love for ZERO effort solutions. Weight loss without willpower? Yes please!
The result?
- Prescriptions for diabetes and weight loss medicines like GLP-1 grew by ~588% globally (2019-2024)
- The GLP-1 market is heading for $170B by 2033 (13% CAGR)
This is triggering a slow yet steady shift in grocery baskets.
- ~79% of users report a total shift in appetite. Their bodies now physically reject high-fat, high-sugar CPG staples
The good news?
- Nutritionists and doctors are recommending more plants; the scientific community is aligned; the meat lobby and the plant-based pioneers are finally looking for the same thing: Nutrient-dense, high-protein formulations that a GLP-1 body won’t reject.
The irony?
- Plant-based brands have been making “GLP-1 friendly” food all along. We just called it “Ethical” or “Vegan.”
- The same mainstream giants that avoided the “Vegan” label are rushing to launch “GLP-1 Companion” lines. (e.g. Nestle, Danone, Conagra, ADM, Chipotle, Shake Shack etc).
- Same formulation. Different label. Overnight profitability.
What makes the GLP-1 segment more appealing than plant-based eaters?
My take:
- Immutable demand – It is not people’s choice but their bodies demanding different foods. Hence, immutable demand.
- Medical legitimacy – Doctor’s orders > personal choice.
- Mainstream identity – GLP-1 users are “regular people losing weight” while plant-based eaters are labelled “fringe” or “extreme”
- Premium pricing permission – “Medical necessity” justifies higher margins. “Ethical choice” triggers price resistance.
- Assured ROI – With India being the “diabetes capital” and growing obesity, GLP-1 usage is inevitable. Hence, demand for GLP-1 compatible food is assured, as is long term scale and ROI.
The market finally believes in plants, they just needed a biological reason to do it.
The strategic opportunity for mainstream CPG brands:
There is a massive silver lining for those willing to innovate.
GLP-1 users (who often are the former heavy users of junk food) now physically reject the oily, sugary, and starchy staples that built your empire. If your portfolio doesn’t pivot to high-protein, nutrient-dense options, you aren’t just losing a “customer segment”, you are losing your most profitable “Heavy Users.”
This is where the Alternative Protein industry becomes your greatest R&D asset.
The “Plant-Based” sector already has the formulations you need. But it’s no longer about “Saving the Planet.” It’s about Saving the P&L.
The strategic opportunity for plant-based/ vegan/ alt protein brands:
Stop fighting the “ultra processed” label or positioning yourself as just a “substitute”. Your products are the perfect antidote to GLP-1 side effects. Hence, you are “Essential Nutrition” for a consumer who needs protein without the bloat and needs sustained weight management.
The Marketing Gap
Mainstream brands have the trust but the wrong message.
Alt-protein brands have the solution but the wrong positioning.
I bridge this gap. I help brands—from pure-play startups to mainstream heavyweights—navigate:
- Go-to-market strategy
- innovation research
- marketing audits
- positioning
- brand identity
- content strategy
- and more…
Want to talk about how to grow your brand? Let’s chat. Write to me at jinal@theveganmarketer.com.
